



**Supplementary Figure 1. Poor coverage of target transcription factor proteins in NIST database**

A histogram of the number peptide MS/MS spectra in the NIST database per target protein demonstrates how underrepresented transcription factors are from current peptide spectral libraries. A majority of our target proteins have no MS/MS spectra in the NIST spectrum library.




**Supplementary Figure 2. *In vitro*-synthesized proteins are enriched full-length proteins (a-b)** Glutathione-enriched protein samples from 46 of the 96 reactions were run on a denaturing SDS-PAGE gel and subjected to either western blotting with an anti-schistosomal GST antibody **(a)** or silverstaining **(b)**. The endogenous glutathione-binding proteins EEF1G and GSTM3 were identified using ‘shotgun’ mass spectrometry. The molecular weight of the full length cDNA is indicated in parentheses. These weights do not include the 26kDa GST tag.




**Supplementary Figure 3. Calibration curve for the schistosomal GST peptide IEAIPQIDK**

A dilution curve of the unlabeled schistosomal GST peptide IEAIPQIDK peptide standard was spiked with a constant amount of the heavy labeled IEAIPQIDK peptide. The unlabeled to labeled peak area was measured by LC-SRM-MS for each standard in triplicate.




**Supplementary Figure 4. Histogram of dot-products for quality score 1 and 2 peptides**

Dot-products were calculated using Skyline and the 2011\_05\_26 NIST release of the H. sapiens Ion Trap peptide spectral library.



**Supplementary Figure 5. Spearman correlation of our empirical peptide ranking with ESPPredictor rankings**

**(a)** Box-and-whisker plot showing the distribution of spearman correlations for the 75 proteins with both ESPPredictor scores and empirical SRM peptide signal intensities. The spearman correlation of these 2 rankings for each protein ranged from -0.45 to 0.85 with an average correlation of 0.47. **(b)** A representative comparison of our empirical signal intensity rank for the STAT5A peptides and the ESPPredictor score rank for the same peptides. This comparison shows a better than average correlation ( $\rho = 0.55$  versus an average of  $\rho = 0.47$ ).



**Supplementary Figure 6. Peptide MS/MS spectrum counts are a poor predictor of targeted peptide signal intensity using selected reaction monitoring-mass spectrometry** (a-b) The NFKB1 (a) and NR5A1 (b) samples were subjected to ‘shotgun’ analysis using data-dependent acquisition. For each peptide, the number of +2 charge state spectra identified in this ‘shotgun’ run is indicated above the SRM signal intensity of that peptide.

Item	Manufacturer	Product #	Cost per unit	Units used per 96 reactions	Cost per 96 reactions
Human In Vitro Protein Expression Kit - DNA (50 reactions)	Pierce	88855	\$515	2	\$1,030.00
Glutathione Sepharose 4B (10mL)	GE	17-0756-01	\$242	0.2	\$48.40
PPS Silent Surfactant (5x1 mg vials)	Protein Discovery	21011	\$199	1	\$199.00
Oasis® MCX plate 30mg/60 µm 1/pkg	Waters	186000250	\$326	1	\$326.00
Sequencing Grade Modified Trypsin (100µg)	Promega	V5111	\$80	0.4	\$32.00
Lab reagents	Various	Various	\$150	1	\$150.00
<b>Total:</b>					<b>\$1,785.40</b>
<b>Cost per reaction:</b>					<b>\$18.60</b>

**Supplementary Figure 7. Reagent cost for generating *in vitro*-synthesized proteins from plasmids**

The reagent usage is based on our current working protocol (Methods). The prices used in this calculation are based on manufacture posted prices on May 24<sup>th</sup> 2011.

## SUPPLEMENTARY DATA LEGENDS

### **Supplementary Data 1. Rank order of proteotypic peptides and fragment ions for targeted proteins**

**(Pages 9-10)** Proteins targeted in this dataset. Columns: Gene Symbol, Gene Description, DNA-binding domain family, mRNA Accession, DNASU Plasmid Repository Clone ID, Page number for targeted data.

**(Pages 11-35)** For each protein monitored in this dataset, the summed peak intensity for each peptide, as well as the relative contribution of each fragment ion to this signal is displayed. Quality score 1 peptides are labeled in green, quality score 2 peptides are labeled in yellow, quality score 3 peptides are labeled in purple, and quality score 4 peptides are labeled in red.




## Proteins Targeted

Gene Symbol	Description	DNA-binding domain family	Accession	DNASU Clone ID	Page
ATF4	activating transcription factor 4 (tax-responsive enhancer element B67)	basic-leucine zipper (bZIP)	CR456384	HsCD00301229	pg. 12
ATOH7	atonal homolog 7 (Drosophila)	basic helix-loop-helix (bHLH)	BC032621	HsCD00077283	pg. 12
BATF	basic leucine zipper transcription factor, ATF-like	basic-leucine zipper (bZIP)	NM_006399	HsCD00301458	pg. 12
BHLHB2	basic helix-loop-helix domain containing, class B, 2	basic helix-loop-helix (bHLH)	BC082238	HsCD00299716	pg. 12
CCDC16	coiled-coil domain containing 16	zinc finger, C2H2-type (C2H2)	BC011584	HsCD00078107	pg. 13
CEBPG	CCAAT/enhancer binding protein (C/EBP), gamma	basic-leucine zipper (bZIP)	BC007582	HsCD00077759	pg. 13
CLOCK	clock homolog (mouse)	basic helix-loop-helix (bHLH)	BC041878	HsCD00299832	pg. 13
CREB1	cAMP responsive element binding protein 1	basic-leucine zipper (bZIP)	BC010636	HsCD00077213	pg. 13
CTCF	CCCTC-binding factor (zinc finger protein)	zinc finger, C2H2-type (C2H2)	BC014267	HsCD00078657	pg. 14
DMRT1	doublesex and mab-3 related transcription factor 1	DM DNA-binding domain (DM)	BC040847	HsCD00300076	pg. 14
DMRTC2	DMRT-like family C2	DM DNA-binding domain (DM)	BC029202	HsCD00299763	pg. 14
E2F5	E2F transcription factor 5, p130-binding	TF E2F/dimerisation partner (TDP)	NM_001951	HsCD00302966	pg. 14
ERG	v-ets erythroblastosis virus E26 oncogene like (avian)	ETS-domain (ETS)	BC040168	HsCD00299791	pg. 15
ETS2	v-ets erythroblastosis virus E26 oncogene homolog 2 (avian)	ETS-domain (ETS)	NM_005239	HsCD00301527	pg. 15
ETV3	ets variant gene 3	ETS-domain (ETS)	BC022868	HsCD00077713	pg. 15
EWSR1	Ewing sarcoma breakpoint region 1	ETS-domain (ETS)	CR456490	HsCD00301321	pg. 15
EZH2	enhancer of zeste homolog 2 (Drosophila)	SANT-domain (SANT)	BC001858	HsCD00076778	pg. 16
FEV	FEV (ETS oncogene family)	ETS-domain (ETS)	BC023511	HsCD00079089	pg. 16
FOSB	FBJ murine osteosarcoma viral oncogene homolog B	basic-leucine zipper (bZIP)	NM_006732	HsCD00301650	pg. 16
FOSL2	FOS-like antigen 2	basic-leucine zipper (bZIP)	BC022791	HsCD00079102	pg. 16
FOXD4L1	forkhead box D4 like 1	Forkhead-domain (Forkhead)	NM_012184	HsCD00302896	pg. 17
FOXD4L2	FOXD4-like 2	Forkhead-domain (Forkhead)	BC103887	HsCD00299718	pg. 17
FOXN1	forkhead box N1	Forkhead-domain (Forkhead)	NM_003593	HsCD00302766	pg. 17
FOXR2	forkhead box R2	Forkhead-domain (Forkhead)	BC012934	HsCD00301098	pg. 17
GATA2	GATA binding protein 2	zinc finger, GATA-type (ZNF-GATA)	BC002557	HsCD00077154	pg. 18
GATA3	GATA binding protein 3	zinc finger, GATA-type (ZNF-GATA)	BC006793.1	HsCD00305430	pg. 18
GF1	growth factor independent 1	zinc finger, C2H2-type (C2H2)	BC032751	HsCD00079248	pg. 18
GMEB1	glucocorticoid modulatory element binding protein 1	SAND-domain (SAND)	BC001473	HsCD00299674	pg. 18
GMEB2	glucocorticoid modulatory element binding protein 2	SAND-domain (SAND)	BC036305	HsCD00299890	pg. 19
GTF2H4	general transcription factor IIH, polypeptide 4, 52kDa	Other	BC004935	HsCD00079304	pg. 19
H1F0	H1 histone family, member 0	Other	CR456502	HsCD00301329	pg. 19
HMGAl	high mobility group AT-hook 1	high mobility group-type (HMG)	NM_002131	HsCD00301489	pg. 19
HMG2	high-mobility group box 2	high mobility group-type (HMG)	BC001063	HsCD00078150	pg. 20
HOXA10	homeobox A10	Homeodomain (Homeodomain)	BC013971	HsCD00078539	pg. 20
HOXA5	homeobox A5	Homeodomain (Homeodomain)	NM_019102	HsCD00304202	pg. 20
HSF4	heat shock transcription factor 4	Heat-shock factor (Heat Shock)	NM_001538	HsCD00302758	pg. 20
HSFY2	heat shock transcription factor, Y linked 2	Heat-shock factor (Heat Shock)	NM_153716	HsCD00302426	pg. 21
ID2	inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	helix-loop-helix (HLH)	D13891	HsCD00301602	pg. 21
ID3	inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	helix-loop-helix (HLH)	BC003107	HsCD00078304	pg. 21
IRF1	interferon regulatory factor 1	Interferon regulatory factor (IRF)	BC009483	HsCD00077440	pg. 21
IRF3	interferon regulatory factor 3	Interferon regulatory factor (IRF)	BC009395	HsCD00079105	pg. 22
IRF4	interferon regulatory factor 4	Interferon regulatory factor (IRF)	BC015752	HsCD00077553	pg. 22
IRF5	interferon regulatory factor 5	Interferon regulatory factor (IRF)	BC004139	HsCD00078081	pg. 22
LEF1	lymphoid enhancer-binding factor 1	high mobility group-type (HMG)	BC050632	HsCD00299770	pg. 22
LHX4	LIM homeobox 4	Homeodomain (Homeodomain)	BC011759	HsCD00077458	pg. 23
LIN28	lin-28 homolog (C. elegans)	zinc finger, C2HC-type (C2HC)	BC028566	HsCD00079059	pg. 23
MAD	MAX dimerization protein 1	basic helix-loop-helix leucine zipper (bHLHZ)	L06895	HsCD00301580	pg. 23
MAX	MYC associated factor X	basic helix-loop-helix leucine zipper (bHLHZ)	NM_002382	HsCD00301600	pg. 23
MEF2A	MADS box transcription enhancer factor 2, polypeptide A (myocyte enhancer factor 2A)	MADs-box (MADs-box)	BC013437	HsCD00299868	pg. 24
MEF2C	MADS box transcription enhancer factor 2, polypeptide C (myocyte enhancer factor 2C)	MADs-box (MADs-box)	BC026341	HsCD00300012	pg. 24
MYB	v-myb myeloblastosis viral oncogene homolog (avian)	SANT-domain (SANT)	AF104863	HsCD00301531	pg. 24
MYBL2	v-myb myeloblastosis viral oncogene homolog (avian)-like 2	SANT-domain (SANT)	BC007585	HsCD00077770	pg. 24
MYC	v-myc myelocytomatosis viral oncogene homolog (avian)	basic helix-loop-helix leucine zipper (bHLHZ)	BC000141	HsCD00076570	pg. 25
MYF6	myogenic factor 6 (herculin)	basic helix-loop-helix (bHLH)	BC017834	HsCD00077638	pg. 25
NFATC3	nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3	Cell surface receptor (IPT/TIG)	BC001050	HsCD00077145	pg. 25
NFE2	nuclear factor (erythroid-derived 2), 45kDa	basic-leucine zipper (bZIP)	BC005044	HsCD00079103	pg. 25
NFIA	nuclear factor I/A	nuclear factor I-domain (NFI)	BC022264	HsCD00077446	pg. 26
NFIC	nuclear factor I/C (CCAAT-binding transcription factor)	nuclear factor I-domain (NFI)	BC012120	HsCD00078641	pg. 26
NFKB1	nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105)	Cell surface receptor (IPT/TIG)	BC051765	HsCD00301116	pg. 26
NR113	nuclear receptor subfamily 1, group I, member 3	Nuclear hormone receptor (NHR)	BC089626.1	HsCD00304068	pg. 27
NR2E1	nuclear receptor subfamily 2, group E, member 1	Nuclear hormone receptor (NHR)	NM_003269	HsCD00305417	pg. 27
NR3C1	nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)	Nuclear hormone receptor (NHR)	BC015610	HsCD00300083	pg. 27
NR5A1	nuclear receptor subfamily 5, group A, member 1	Nuclear hormone receptor (NHR)	BC032501	HsCD00299843	pg. 27
OLIG1	oligodendrocyte transcription factor 1	basic helix-loop-helix (bHLH)	BC033290	HsCD00076967	pg. 28
OTX1	orthodenticle homolog 1 (Drosophila)	Homeodomain (Homeodomain)	BC007621	HsCD00077740	pg. 28
PATZ1	POZ (BTB) and AT hook containing zinc finger 1	zinc finger, C2H2-type (C2H2)	CR456613	HsCD00301150	pg. 28
PITX3	paired-like homeodomain transcription factor 3	Homeodomain (Homeodomain)	BC011642	HsCD00078535	pg. 28
PLEK2	pleckstrin 2	Other	BC001226	HsCD00077265	pg. 29
POLR2F	polymerase (RNA) II (DNA directed) polypeptide F	Other	CR456546	HsCD00301192	pg. 29
POU1F1	POU domain, class 1, transcription factor 1 (Pit1, growth hormone factor 1)	POU-domain (POU)	NM_000306	HsCD00302903	pg. 29
POU3F4	POU domain, class 3, transcription factor 4	POU-domain (POU)	NM_000307	HsCD00303140	pg. 29
POU4F1	POU domain, class 4, transcription factor 1	POU-domain (POU)	NM_006237	HsCD00302919	pg. 30
POU4F3	POU class 4 homeobox 3	POU-domain (POU)	BC104923	HsCD00300001	pg. 30
PPARA	peroxisome proliferator-activated receptor alpha	Nuclear hormone receptor (NHR)	CR456547	HsCD00304173	pg. 30
SF3A2	splicing factor 3a, subunit 2, 66kDa	zinc finger, C2H2-type (C2H2)	BC004434	HsCD00079081	pg. 30


Gene Symbol	Description		Accession	DNASU Clone ID	Page
SOX10	SRY (sex determining region Y)-box 10	high mobility group-type (HMG)	CR456584	HsCD00301364	pg. 31
SOX5	SRY (sex determining region Y)-box 5	high mobility group-type (HMG)	NM_006940	HsCD00301463	pg. 31
SREBF2	sterol regulatory element binding transcription factor 2	basic helix-loop-helix leucine zipper (bHLHZ)	CT841522	HsCD00301198	pg. 31
STAT5A	signal transducer and activator of transcription 5A	Signal Transducers and Activators of Transcription subdomain (STAT)	BC027036	HsCD00076786	pg. 32
STAT5B	signal transducer and activator of transcription 5B	Signal Transducers and Activators of Transcription subdomain (STAT)	BC065227	HsCD00299823	pg. 32
TAF11	TAF11 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 28kDa	Other	NM_005643	HsCD00301672	pg. 32
TEF	thyrotrophic embryonic factor	basic-leucine zipper (bZIP)	NM_003216	HsCD00304220	pg. 33
TFAP2A	transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha)	Transcription factor AP-2 (AP2)	BC017754	HsCD00077076	pg. 33
TFAP2B	transcription factor AP-2 beta (activating enhancer binding protein 2 beta)	Transcription factor AP-2 (AP2)	BC037225	HsCD00076757	pg. 33
TFCP2L1	transcription factor CP2-like 1	CP2 transcription factor (CP2)	BC064698	HsCD00299737	pg. 33
TFCP2L4	transcription factor CP2-like 4	CP2 transcription factor (CP2)	BC036890	HsCD00299801	pg. 34
TFDP2	transcription factor Dp-2 (E2F dimerization partner 2)	TF E2F/dimerisation partner (TDP)	BC021113	HsCD00299708	pg. 34
TGIF2	TGFB-induced factor 2 (TALE family homeobox)	Homeodomain (Homeodomain)	BC012816	HsCD00079074	pg. 34
TP53	tumor protein p53 (Li-Fraumeni syndrome)	p53-like DNA-binding (p53)	BC003596	HsCD00078349	pg. 34
TP73L	tumor protein p73-like	p53-like DNA-binding (p53)	BC039815	HsCD00299815	pg. 35
XBP1	X-box binding protein 1	basic-leucine zipper (bZIP)	CR456611	HsCD00301204	pg. 35
ZMAT5	zinc finger, matrin type 5	zinc finger, C2H2-type (C2H2)	CR456353	HsCD00301319	pg. 35
ZNF496	zinc finger protein 496	zinc finger, C2H2-type (C2H2)	BC007263	HsCD00077733	pg. 35
ZNF530	zinc finger protein 530	zinc finger, C2H2-type (C2H2)	BC060865	HsCD00301131	pg. 36
ZNF70	zinc finger protein 70 (Cos17)	zinc finger, C2H2-type (C2H2)	CR456615	HsCD00301373	pg. 36
ZNF74	zinc finger protein 74	zinc finger, C2H2-type (C2H2)	CR456616	HsCD00301379	pg. 36

## Table Legend


Peptide Quality Score
1
2
3
4




Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
AEQEALTGECK	2	19	27	16	17	13	6									
AGSSEWLAVDGLVSPSNNSK	2	2	2	23	28	8	2	8	10	6	7	2				
EDAFSGTDWMLEK	9	8	8	6	5	22	33	7	2							
DLIEEVR	10	41	49													




Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
DHYLFFPGAK	2	35	2	29	14	17										
LPGESELYSQR	10	14	13	7	21	6	30									
MQGLTAFDR	6	8	8	18	5	56										
VAPPCAGGTCEAGTCAGAGR	2	11	6	7	3	11	8	11	6	4	7	16	8			
ILAEAEER	9	9	82													



Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
ADTLHLESEDEK	12	8	4	12	19	26	18	1	0							
QLTEELK	18	25	58													




Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
ALTNLDQQQK	4	5	9	34	31	7	5	4								
EVLGYLAK	9	41	23	27												
IIALOSLQAGELSGR	8	7	2	11	11	9	3	12	21	9	3	4				
INEGIAQLK	6	28	14	20	32											
IPSAGPPACLPK	2	2	0	4	12	72	1	2	4							
ISAPLLMPQR	17	20	22	7	22	6										
LTLGHLEK	7	4	24	18	48											
NCVPIVQR	2	1	80	16												
NVETGQEMFCSGFOTCAR	7	16	11	4	10	13	16	15	7	2						
VVSELOGGTSR	1	3	25	20	17	8	3	23								
AVVLELTLK	3	5	17	27	49											
DLLPEHLK	7	1	75	16												




Peptides	Relative Contribution of Transition to Signal (%)																	
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18		
APIPHSGSIEK	0	1	3	7	5	71	8	4										
ATLWQVQVSTSAWTTNPK	5	7	8	13	8	4	5	2	2	42	4							
ENTAEALPEGFDDPEVDAR	6	4	0	44	7	3	5	2	5	1	24							
EVTSSVLPNDFSTNPK	22	4	2	5	2	3	1	1	47	12	1							
LGQLSCALCNTPK	16	6	4	13	9	10	12	23	7	0								
QKDEIQECCR	10	20	11	8	11	21	9	1	10									
SELLWQTHVLGK	15	9	8	13	13	31	10	3										
IESPFAK	5	15	80															
EASQGSASSAPQSVK	5	1	29	8	8	15	8	9	5	11	0	0						
GDASKPLSDAQGK	3	15	3	6	3	66	3	2	1									




Peptides	Relative Contribution of Transition to Signal (%)																	
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18		
AQDTLGR	22	78																




Peptides	Relative Contribution of Transition to Signal (%)																	
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18		
DOFNVLK	13	7	17	63														
BTAGDSEIR	3	7	12	9	29	16	10	14										
ELGMLPGNAR	0	2	60	14	7	3	14											
EMCTVEEPNEEFTSR	5	7	4	1	1	42	13	21	4	2								
EPSTVEYVK	12	22	36	10	20													
FLFLDHR	9	19	72															
ILSTHLLSDSLTPPEYLK	4	20	34	13	1	4	3	6	8	5								
LATPQFK	7	4	46	42														
MULTYSCSK	4	17	12	24	43													
NQLFCCHMLR	9	8	14	10	22	21	17											
VCFVATVR	4	15	19	62														
CHEHLMQYK	4	65	12	16	2	1												
ELGIESLPETAADK	5	5	4	2	41	9	11	11	11	0	2							
IPDTSTPPR	20	9	9	19	18	26												




Peptides	Relative Contribution of Transition to Signal (%)																	
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18		
ILNLLSDAPVPR	1	3	24	16	5	11	25	5	4	6								
TLIEELK	3	13	85															
WAVLEGNK	2	10	26	35	27													




Peptides	Relative Contribution of Transition to Signal (%)																	
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18		
CDQDVACR	23	23	19	24	11													
CPDCDMFYTSSELV	4	1	5	9	22	16	17	13	7	4	1							
CSMCDVASVEVK	10	15	5	14	14	10	12	13	7									
FHCHPCHDTVIAR	3	2	13	4	8	5	52	13										
FTSGSTMK	2	8	33	56														
HADNCGAPDQVEGENGETK	1	4	14	14	2	15	13	1	20	1	5	9	2					
QLLDMHFK	10	28	29	33														
TFQELCSYTCPR	11	12	8	17	22	12	7	9	1									
VVGNMKPKPTK	21	3	3	46	9	5	1	13										
YALQIHK	15	18	31	36														
YCDVAFHER	9	28	13	17	33													
YHDPNFVPAAFVCSK	10	7	5	3	1	39	6	2	1	21	4							
DPDYQPPAK	4	59	8	12	17													
QHSYEEQK	13	16	14	10	47													
SDLGVHLR	20	9	56	15														




Peptides	Relative Contribution of Transition to Signal (%)																	
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18		
GLPQPYVPGQTGNQWQMK	3	4	1	1	4	5	1	3	76	2								
MVIQDIPAVTGR	4	1	2	46	9	21	12	6										



Peptides	Relative Contribution of Transition to Signal (%)																	
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18		
ENAPQPTPHGAVLLAPTPPK	6	55	1	13	11	2	2	1	0	2	0	5	0					
GTTQPVPSK	3	33	8	1	52	1	2											
LCLFAACEHK	9	5	23	12	31	20												
TSQSEWQLGQEAALVGLK	24	13	8	7	3	3	7	7	5	8	11	4						




Peptides	Relative Contribution of Transition to Signal (%)																	
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18		
AAADTLAVR	11	10	18	20	41													
FVSLLEAK	2	5	11	6	77													
LWLQSK	4	5	14	77														
NVMDSINNR	6	3	12	10	20	49												
AEIELELK	3	5	14	30	48													
DGVDLK	12	74	14															
IYDTNVLGDLIEK	3	7	14	2	17	12	26	8	4	7	0							
SLGLTTK	4	7	3	86														
SSMATONLPEQHYER	10	4	7	6	1	54	8	8	1	0								




#### Relative Contribution of Transition to Signal (%)

Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
MTDPEVAR	4	10	5	57	24											
NTGGAFFPNTSVPEATOR	5	5	1	31	15	2	4	1	0	37						
QWLEWAVK	15	30	27	28												
VPOQDWLSQPPAR	2	38	9	16	10	9	7	6	3							
YYTDNMTK	9	2	3	11	16	59										
AAQSPSTVVK	2	2	2	9	4	80	0									
ETPLHLTSDVDK	8	9	1	4	16	15	3	42	1	2						
EYGLPDVNIILFQNDGK	10	2	8	9	26	19	13	3	6	3	0					
MVSPPTVGMNYSYMEEK	2	6	11	4	18	12	18	5	21	4						
TEMTASSSDVGTSK	9	7	8	10	4	8	12	12	18	8	4	1				
MECNPSGVNSGR	6	16	10	5	5	42	11	5								
VIVPADPTLWSTDHVR	13	2	1	10	20	7	4	29	2	2	10					




#### Relative Contribution of Transition to Signal (%)

Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
AMISQALK	3	2	20	75												
FGMNGMLCNLQK	8	12	20	17	18	3	12	8	1							
LADPEVAR	4	11	7	54	24											
NMDQVAPVANSYR	2	2	4	1	38	34	10	4	5							
SCGSFISWTGGWFEK	5	3	13	2	13	15	10	27	10	2						
ATFSGFK	7	21	71													





#### Relative Contribution of Transition to Signal (%)

Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
LWMNYPFNIR	3	2	3	41	9	6	31	4								
AGCSIVEKPEGGGGYQFPDWAYK	14	34	3	34	8	2	1	1	2	1	1					
CKPQMNYDK	3	4	8	2	84											





#### Relative Contribution of Transition to Signal (%)

Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
AAWVFDQK	8	11	34	29	19											
AGWVQCPNPGCGNQFAWR	15	9	9	6	3	10	5	4	38	2						
GDATVSYEDPPTAK	1	6	56	3	4	6	20	4	1	0						
GGPGPPQLMEQMGGR	7	6	6	7	6	1	12	10	25	13	3	2	0			
TQPMHLYDK	5	13	6	15	6	4	51	0								
APKFEGLPPFPFGGDR	1	1	3	3	18	1	3	8	55	5	1	2				
GMPPPLR	12	30	58													




Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
ECSVTSLDLDFPTQVIPLK	51	11	2	1	1	13	6	7	3	2	2					
EFAAALTAIR	6	21	23	23	13	14										
FCQCSSECONR	20	6	2	19	50	2	2									
QCPCYLAVR	10	10	11	7	61											
TELNQEWK	3	4	24	31	38											
VLGTTTQNFCAIAR	5	7	10	7	11	17	21	11	3	7						
IQPVHILTSVSSLR	2	3	13	4	10	23	13	11	2	19						
SMFSSNR	8	2	90													
YDCFLHR	26	31	43													
AIQTGEELFFDYR	10	15	22	12	9	3	13	16	1							
QCPCSSCPVIAGNFCKE	6	11	19	7	31	12	4	1	10							
VMMVNGDHR	2	12	27	28	31											
YSGADALK	15	11	33	41												

Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
ANAGCIWEGGHGFEK	1	10	4	3	17	11	18	24	7	2	1					
LPAGLAPFPQLSK	1	1	23	1	14	1	36	14	1	3	3					
LTDPEVAR	4	10	6	54	25											
NPSWGPLSPAVOK	3	1	22	8	1	18	33	10	4							




Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
AELSEIAELQK	9	11	19	12	7	24	11	7								
EETLTPEEEK	1	4	2	58	23	5	7									
IPVEEGQPGPLAEVR	3	4	1	5	2	12	4	25	10	5	4					
TSGSDQSPDLNPSLLAR	5	2	3	14	11	8	1	35	3	2	17	0				
HQAETDQLEEEK	8	8	8	13	5	7	11	40								
LEFLVAHPGCK	2	41	9	9	15	11	9	2	1							


Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
LOAETEELQK	4	7	6	6	6	14	11	47								
QPLEEDSPSSSAGLDK	2	12	6	6	5	3	3	24	16	10	9	4				
SGGSGVAVVK	5	4	3	48	17	8	6	9								
SPPAPQPMR	5	2	1	3	37	6	45									
EIAELQK	29	22	49													
TGTTVGR	2	5	4	90												
GSSGSPAAHAEYSGGGGQK	2	7	7	9	12	13	12		15	7	12	4	1			
LEFLVAHPGCK	1	11	25	16	17	14	9	4	3							




Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
FLEGLDPQLQIAR	3	4	2	2	58	14	6	8	2	1						
HNLSDNCFVK	3	20	5	8	7	28	31									
LTLSDGICAFISGR	10	7	7	7	25	7	14	17	5							
WGGVALPR	9	51	11	29												
YLLSAPVYAGAK	1	3	2	1	1	30	11	29	14	8						



Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
EADLSALR	8	31	18	26	7	11										
YLLSAPVYAGAK	1	4	3	3	1	27	11	28	14	8						
HNLSDNCFVK	6	20	5	7	5	23	34									
EHEGGGGPSPSEFOTK	8	12	4	1	46	3	1	6	3	5	1	6	3			




Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
GGLWLNPAK	14	10	12	22	29	13										
LLAEPSPAR	2	1	51	8	39											
GGLLMQAPLPGSPAPOSK	0	13	1	8	1	1	32	1	2	34	7	1	0			
GSHAFPHYK	24	10	2	45	18	1										
HAGFSCSFVSDGPPER	1	3	74	1	6	3	3	4	3	2	1					
MOEELQK	8	11	80													
TAPDGWK	8	6	86													




Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
LWQINDEK	1	5	19	30	44											
NELFLPCTDQCSLAEQILAK	18	12	23	8	12	4	6	6	5	4	2					
NIPKCELVQEIYFTR	4	12	16	9	7	13	7	21	2	10						
VVESLPSSSEGSFLQK	1	15	8	2	2	3	4	3	2	58	1	1				
EDLNIISPFPPQPK	3	30	1	8	2	21	29	3	3	1	0					
VGMKPPMPQK	6	9	0	5	64	6	6	3								







Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
ECVNCGATPLWR	1	33	11	9	13	4	14	6	7	2						
GAECFEELSK	12	15	19	27	20	7										
NANGDPVCNACGLYYK	20	2	8	10	6	7	16	2	28	1						
YQVSLTESMK	7	4	8	5	29	47										




Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
DVSPDPSLSTPGASGAR	1	4	3	1	2	34	9	21	5	3	15	1	2	0		
ECVNCGATPLWR	1	31	7	10	15	4	16	7	7	3						
NANGDPVCNACGLYYK	16	3	10	8	7	8	17	2	28	1						
NSSFNPAALSR	4	6	3	42	18	12	14									
YQVPLPDSMK	4	1	20	2	54	19										
VHSLEDFPK	21	8	3	3	12	53										




Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
ASASPSDCEGSVCR	11	7	5	17	7	6	14	5	24	2	0					
LENVPASR	2	2	81	3	12											
LLLGGGSYK	1			4	27	68										
LSPESQLTEAPDR	12	19	8	19	11	4	17	4	5							
SPFGDYSLR	8	22	15	18	38											
VESELLCTR	12	20	15	5	49											
SHSOTRPFACMCKG	6	2	87	3	0	0	0	0	0	0	0					
TFGHAVSLQHK	4	8	6	22	22	30	2	8								
AFSQSSNLITSR	9	28	15	3	5	11	23	2	5							




Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
FNDQLSPK	47	10	9	6	28											
FYCRGINK	4	3	4	56	32											
GIADVGLMEEVCNIQK	5	10	20	15	8	8	13	13	2	7						
MMDSGQIDFYQNDK	12	7	11	15	26	15	3	6	4	2						
SQTQNVLMVSTPKPK	18	1	6	2	3	1	27	12	13	15	2					
YATVSSAK	3	10	24	13	50											
AVILETLR	2	7	36	31	24											
DSEIESEDTLMLWK	12	12	4	4	8	7	41	9	3	0						
FOLLISSAR	1	17	46	20	16											
EIEELLR	13	41	46													
HFWHLGAK	25	17	15	43												
NQVEQEGEEFLYTLTLER	8	7	15	11	19	20	10	8	2							




Peptides	Relative Contribution of Transition to Signal (%)																	
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18		
CVQYDEIVSFK	32	9	5	6	7	12	17	13										
DLAALGQCDHR	10	6	13	11	14	26	12	6	2									
EFVHLGAK	24	27	28	20														
FVCPGIVNK	6	6	8	48	33													
MAEEGENLEAEVYPTGDSR	0	3	4	7	1	43	23	10	4	2	2							
VQDFPLQLR	2	1	8	72	16													
VVSTLPSTVLGK	4	2	1	1	49	5	4	33										
DANLNNVONFGMLDLVK	7	17	9	4	13	6	9	9	20	4	2							
ILDSGAR	10	29	61															
IMDSGELDFYQHK	18	5	10	16	17	12	3	8	6	6								
MNGIMLR	36	8	57															
SOHLSNVLMTLPVSLPPVK	3	14	48	3	2	0	8	7	3	5	3	2						




Peptides	Relative Contribution of Transition to Signal (%)																	
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18		
AGEESTLGLSLR	6	13	11	3	13	9	15	10	10									
AWSDTSQLGPK	7	23	8	2	7	6	6	7	34									
EFGLVFOR	28	43	4	25														
ELGVLVFNLSAK	2	5	5	25	22	29	2	10										
PFMIVVAQVTR	2	5	17	32	20	9	14											
LYGHPTCLAVFR	2	2	2	4	5	80	1	3										
NLQDFLGGLSFGLVLR	5	1	1	21	16	3	8	26	10	5	3	0						
QTPVLPPTTIDQIR	5	1	2	1	2	6	69	5	1	8								
ELPSLAK	4	21	75															
LMVYTPAGHSQVK	1	3	2	4	3	43	22	14	9									
MLFLEQPLQAALVVK	2	1	4	2	1	2	1	28	3	54	2							
AHPVMLK	9	3	88															
ESVGDAAISGITAGIHFRLR	8	26	13	3	6	6	7	15	1	7	9							
IALLGGK	2	18	21	58														



Peptides	Relative Contribution of Transition to Signal (%)																	
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18		
VGENADSQIK	4	20	27	18	24	8												
YSDMVAIAIQAEK	5	6	7	10	21	35	10	2	3									
GVGASGSR	2	10	26	5	57													
LVTTOVLK	4	4	5	86														




Peptides	Relative Contribution of Transition to Signal (%)																	
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18		
EPSEVPTPK																		
SGQPLAK																		
MSESSSK																		
TTTTPKR																		




Relative Contribution of Transition to Signal (%)

Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
LGEIMNSEQSAK	7	5	7	33	31	14	3									
MSSYAFFVQTCR	7	14	15	21	24	14	3	3								
SEHPQLSIGDTAK	8	1	7	3	6	2	8	64	1							




Relative Contribution of Transition to Signal (%)

Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
EESSYCLYDSADK	3	12	15	19	13	22	7	3	6							
EFLFMVLTAR	9	17	13	26	23	12										
GENANWLTAK	17	8	9	17	27	10	11									
GFELPPALASGADAAR	8	1	1	1	5	10	14	6	4	17	34	0	0			
GPPPDGALGTSSQVPPGYFR	1	2	39	1	31	2	4	3	4	2	9	2				
VSMIAELAPFPR	1	26	19	12	11	17	9	4	2							
HQTLELEK	23	9	8	60												
LSGAYGTAK	3	14	20	37	25											
SVHLTDR	24	50	25													





Relative Contribution of Transition to Signal (%)

Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
IEIAHALCLSER	4	3	9	19	29	12	4									
LHSHDNGGPEK	1	8	18	4	8	7	8	23	16							
NSLSNSGASADAGSTHSRR	21	8	7	4	2	7	15	6	5	9	2	6	4	2		
SYAASAAAPR	1	1	27	16	10	19	9	11	5	3						
YGYGNGMLSVGR	4	13	14	10	4	17	17	6	13	1						
YQTLLELEK	8	8	10	74												





Relative Contribution of Transition to Signal (%)

Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
DHVEFHQHSFVR	1	2	27	16	10	14	20	9								
EVLPQYFK	7	4	73	15												
GSFPEGPR	6	24	42	22	6											
LIQCLFQPLAAGPSNAGGK	7	6	3	1	7	16	12	3	0	13	24	9	1			
LLGEVQALR	3	9	13	3	71											
LSLMLDEGSSCPPTAK	19	1	11	6	6	5	17	8	17	9	2					
LWALVDPGPDHLIR	1	12	1	1	1	54	3	17	7	1	1					
QIWALALTPGAPSSLTSSQK	4	6	1	2	1	19	3	1	23	25	11	3	1			
QLMVYGR	31	32	10	26												
QQNEIWR	48	27	8	21												
WSPSGTFLVSDQSR	8	4	23	17	12	9	11	3	6	4	3					
GEPELAWK	3	7	5	86												
GPLGLESDR	3	30	18	9	30	11										
QVQSTEAR	9	11	28	33	19											
HSNMASFYR	3	10	15	17	56											
NAQQPEPQPR	3	6	2	7	3	23	55									
VVSEIQGLLRPER	57	13	7	5	5	5	2	3	1	2						
WRPEDLGR	61	6	1	32												




Peptides	Relative Contribution of Transition to Signal (%)																	
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18		
FYYNPNFK	2	28	14	56														
GYPQLLVR	9	26	15	50														
IFQDAIK	6	4	24	67														
NLNMPLTR	2	31	16	51														
QIANSVPR	21	5	10	10	13	19	22											
QLNLVGFSK	4	32	37	10	17													
SAFLATLSEEK	3	14	7	10	22	31	11	3										
YPLVSVNEAPYR	7	11	4	11	7	33	17	10										
MASPISTLNEEDFNK	59	7	18	12	2	1	1	0	0	0								
NMLPAGNFWLQMPFIADR	11	3	2	27	13	11	8	2	21	1	1							
DELTASEASTR	3	10	7	19	24	31	7											
IVESDQFK	3	3	15	79														
LALDPSPLDK	3	20	4	61	6	5												
SBDWENGTGVNEELFK	5	9	7	27	19	17	5	7	2	2								
SPLCEHTFPDSDLR	16	14	16	30	5	9	10	0	0	0								

Peptides	Relative Contribution of Transition to Signal (%)																	
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18		
ELVSPQNK	0	35	3	5	53	3												
NSLSDHLSGISR	1	12	8	20	22	9	23	5										
TPVDDPMSLLYNNMDCYSK	8	14	6	9	9	17	20	14	3									




Peptides	Relative Contribution of Transition to Signal (%)																	
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18		
ELVGVPR	1	11	82	6														
GCYEAVCLLSER	11	4	8	28	17	18	9	5										
GTQLSQVEILQR	14	10	16	13	9	28	10	0										
GPAAEELSLDDMNHCSYR	10	15	9	8	18	15	11	10	4									


Peptides	Relative Contribution of Transition to Signal (%)																	
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18		
CAMNSLPRIEEK	3	6	7	2	46	9	11	10	7									
EEMFQIPWK	36	9	7	35	8	6												
EPEIDSPGGDGLSLQR	2	12	2	10	10	2	2	3	30	13	11	2						
GYLLNEPGVQPTSVYGDFSCK	11	12	4	14	18	4	5	1	27	3	1							
LLEGSEWPTNVGDK	13	6	5	2	53	4	9	3	5	1								
NMDATWLDLSTPVR	20	20	7	3	8	12	13	9	5	2	2							
HGWDINK	62	12	26															
MLPLTLK	1	8	92															
SWAHTGR	8	27	16	49														




Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
DGGGCAHVPQGLGR	1	5	2	73		10	5	1	3	0						
DKPDLPTWK	1	15	17	4	64											
LVGSEVDR	4	8	3	4	81											
QVFGQTSCEGLR	7	1	18	10	26	10	15	7	3	4						
TLPGWPVYTLPPQMSLTDK	1	1	2	0	0	48	1	23	4	5	1	14				
AGOWLWAQR	16	39	24	21	1											
EGGVFDLGFPIVGSWAPR	8	3	3	17	11	4	1	17	27	6	3					
GVMSYVR	8	35	57													
HVLSCLGGGLLWR	2	4	1	3	4	15	7	6	17	41						
SDYLHGR	49	31	20													
ILPWLVSLDQLGQEGVAWVK	12	17	25	2	14	7	5	2	9	4	2					





Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
EGIDKDPPTWK	2	3	88	0	5	1	1	0								
FVTLFCQGEFFDQDR	36	2	20	10	4	2	10	7	8	2						
GGGFMSAVSCGNGK	2	7	6	24	11	10	20	5	12	2	0					
GVVLWMAPDGLYAK	4	1	7	1	25	22	23	14	3	0						
LHCLLYR	3	5	33	59												
EDGKQDPTWK	1	1	23	21	25	15	5	9								
LLSHLR	8	5	6	7	12	12	13	19	13	5						
QWLDQIDSGK	14	13	5	8	30	16	13									
SAEALAFSDCR	3	12	27	35	13	8	2									
SNDFEELVER	12	14	19	24	15	16										
SGLDISDPYK	23	4	10	10	21	33										
EEDALFK	25	32	13	31												
ELTTSSPEGCR	11	2	27	27	15	18										
GVDLPEHNSPEDYHR	17	6	1	21	5	26	11	6	2	6						
LFDTQFLSELGAFHHGR	18	14	11	9	9	7	8	3	13	8						
LLSHLR	16	13	71													
YPLGVWENEK	2	10	10	32	25	4	18									
DYVPDQHPPEIPYQCPMTGPR	12	7	4	1	17	7	3	1	42	4						



Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
ALTSINPHGCR	9	4	30	11	29	7	11									
DMPFPQYK	12	1	17	70												
ELHHWQSQQR	1	9	7	37	23	23	1									
FPSPEIDPSDK	3	35	13	5	4	23	16									
FTFNGLDYLDR	8	13	17	21	16	5	7	13								
QLILQLGQDLYAR	12	9	8	5	3	25	14	16	6	2						
HGPSQGDNTIFK	5	3	28	1	27	8	2	5	20							
LITVQVVAAR	1	1	24	18	17	24	5	9								
LQISNPDLK	1	16	4	21	59											
MLPSLSLTDK	3	3	8	6	20	12	13	36								
VFWSGPCASAHSDCPNQR	2	17	1	18	5	20	10	12	7	7	2					
YTEGVDEADPAK	29	4	5	5	19	4	16	17								
LFCIPWR	29	15	55													
LYDQPR	30	6	64													



Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
QPYPSLSVTSMSR	2	4	13	13	7	28	9	8	4	9	2					
ESAAINILGR	15	12		51	13	7	2									
SSLVNESEIPASNGHEVAR	1	2	2	1	2	3	2	66	14	6	1	1				
DEGDPQK	21	13	66													
KPLNAFMLYMK	11	11	7	8	12	27	24									
QLHMLQYQWSAR	6	1	2	46	12	9	13	8	3							





#### Relative Contribution of Transition to Signal (%)

Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
CADCOMQLADR	18	17	12	17	9	9	18									
CTACCGQIPPTQVVR	1	2	0	2	80	2	8	3	1	1	0					
EDQLSELGHTNR	5	6	16	12	6	26	23	4	0							
EQLSSETGLDMR	7	2	12	16	9	17	24	14								
ESSAEDCGVSDSELSFR	11	9	3	13	5	32	4	12	7	6						
QLATQDEFLMEDQR	7	12	18	15	14	10	6	4	8	6						
VVQVWFQNR	7	20	35	21	16											

#### Relative Contribution of Transition to Signal (%)

Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
AADPEQLLHGAGICK	2	9	4	24	23	12	7	2	18	0	0					
AAEAPPEAPEDAAR	6	2	0	16	10	5	2	53	5	1	0					
AGVALDPVDFVHQSK	3	17	4	5	4	3	1	6	51	6	1					
EGEAVEFTFK	8	14	45	18	14	2										
MGFGLSMTAR	4	7	29	25	9	22	3									
VTGPGVFCGSR	3	16	6	11	32	6	8	8	3	6						
AQQGPSAGGKPTFYR	2	2	38	3	15	8	5	3	9	11	3					
LHMEGRF	12	14	73													




#### Relative Contribution of Transition to Signal (%)


Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
AVHQDQLQR	3	21	17	26	27	5										
EAEHGASMLPYNNK	15	3	50	6	3	5	7	3	8	1						
GLVPLQPESSR	3	1	7	30	8	51	1									
GSMQSLGSDGYSSTSIK	9	5	6	11	2	8	6	5	8	29	6	6				
HTLSLLIK	14	6	10	10	61											
MDSIGSTVSSER	4	12	6	8	10	47	5	8								
MNQMLLEADYLER	1	7	5	9	14	18	20	13	9	3						

#### Relative Contribution of Transition to Signal (%)


Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
ATEYQYMR	14	26	22	23	15											
DSVPSLOGEK	3	2	3	8	82	2										
DSFHSRLR	42	45	13													




Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
ASPNLGATGANSLSLK	2	3	3	2	8	9	6	43	18	4	1	0				
GMMPLNTOR	3	6	6	29	52	4										
INEEFDNMR	4	15	16	28	16	21										
LFOYASTDMK	7	5	7	19	22	29	10									
TNSDVEALNK	6	12	16	27	10	7	22									
VVPPSSK	1	9	51	39												
GCDSPDPDTSYVLTPTHEEK	3	11	3	46	12	10	7	2	3	3						
SEPSPPR	8	51	11	30												
YTEYNEPHER	7	3	47	8	14	12	8									
SPVDSLSLSSSSSYDGSDR	1	1	4	2	1	2	3	7	28	26	26					
SPVDSLSLSSSSSYDGSDR	1	19	5	5	5	5	6	12	15	22	2	4				





Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
INEDLMIKR	9	12	12	25	11	14	17									
LFOYASTDMK	5	5	7	18	23	30	12									
NSPOLLYSPGNLTK	1	1	1	21	30	20	14	2	3	6						
NTMPSVSEVDLLNLR	13	18	12	9	11	6	7	4	18	2	1					
TNSDVELR	6	15	32	14	9	25										
SPVDSLSLSSSSSYDGSDR	2	22	8	5	6	6	10	8	14	17	2					
SEPSPPR	7	41	6	45												
SPVDSLSLSSSSSYDGSDR	3	3	8	6	7	4	21	48								



Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
ASQPAVTSFK	2	6	7	19	7	4	54	0								
CMVHOGTILDQWK	16	10	9	3	2	22	8	18	11	2						
LVTVTPFHR	2	30	15	36	17											
LVEQNGTDQWK	6	8	5	17	20	8	36									
MEGNITSSGAR	3	7	9	20	28	19	8	7								
SLASPLQPCSTWEPASCGK	4	10	2	50	6	3	2	2	2	1	19					
VIANTLPIK	20	13	9	12	46											
VLNPELIK	5	2	32	62												
HALAAGEIK	4	3	9	20	64											
SILESSPR	3	25	21	51												
VIELVQK	5	8	86													
ELELLMSTENELK	1	9	5	8	21	24	23	8	1	0						
YVNAFSAR	9	11	12	67												





Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
DQLEFQK	5	19	36	40												
EQEPDTDAVR	7	3	7	8	5	31	4	31	4							
LDGHTSDLSR	21	3	19	22	31	1	2									
QDTLESPSLTSTPVCQK	5	10	1	33	5	7	8	1	1	19	10					
QRALVPVTR	1	3	1	2	68	13	5	1	7							
SLASPLQPCSTWEPASCGK	3	5	9	17	11	25	12	18								
SLSLPTTAPNSSSLQK	5	10	5	6	1	2	2	3	2	2	52	9	3			
VDTGGLESK	4	19	11	7	13	19	27									
VLNPDQK	4	3	29	63												
EDNLLNOGFLQAKPEK	42	9	5	5	4	2	13	6	10	4	1					
FLASHFPNR	22	24	11	14	29											
HAAPVTFQK	2	34	14	5	10	35										
QWTLQK	32	21	47													
SHFTTAPMSSAWK	2	3	15	0	13	2	40	8	15	14						
VVVTTLR	0	19	9	30	42											
YSMDNTPHTPTPFK	21	2	19	10	3	31	4	4	4	1						
LMMSTLQK	1	1	11	87												
QEGQDNK	24	30	6	41												
SEAGLIEDDIRPEK	6	7	19	9	5	12	19	13	7	2						
TLPFSPQFLNFWNK	12	9	10	6	8	2	3	38	12							
TPELEEFK	10	8	9	7	54	12										



Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
ATAVLSYQAEQK	5	6	9	10	9	25	26	8	1	0						
DOIFLENNEK	1	4	3	5	2	81	5									
FELLPTPLSPSR	2	2	1	2	11	2	75	3	2							
LASYQAAK	7	15	10	68												
LISEEDLLR	3	4	7	5	81											
SGLCSFSYVAVTFPSLR	2	0	21	25	7	19	10	3	2	11	1					
SSDTEENVK	5	12	16	22	44											
THNVLER	10	14	76													
DSGSPNPKR	8	3	63	5	21											
NIQDCMWSGFSAAK	6	7	14	2	14	18	17	6	8	8	1					

Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
CLSSVDSISSEER	1	5	12	4	12	17	27	5	6	12						
EGGASIDSSASSSLK	3	5	8	7	8	16	34	9	10	1	0					
INEAFEALK	8	8	26	22	36											
MQELGVDFPSYRPK	3	2	4	1	58	10	2	12	4	3						
QENLEGADFLR	12	7	4	39	23	6	11									
SASVIER	7	17	56	29												
TCSSQWPSVSDHSR	12	2	9	2	4	53	12	1	2	3						
GLVTAK	12	25	63													
LPCVEEYVEK	13	10	7	21	21	28										
LDLLELR	11	20	69													
TVANPNQR	2	31	12	55												




Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
ESSLSPPASSISRR	3	1	2	4	1	14	4	53	16	1	0					
NYEGTCEPEK	2	62	5	2	4	2	12	11								
VLSLQIASIPVECSQR	1	3	1	51	6	11	18	7	1							
DHLVLRLEPSYR	0	14	2	1	45	15	14	10								
FTTTPVLMK	8	2	29	16	46											
DMSQISVSGAGVSR	1	10	4	14	5	11	39	12	2	1						
TVATASQEIISTK	12	15	11	9	4	8	5	17	7	4	7					
VHWPQSK	1	25	3	46	22											
YLRPHAFQVHR	9	1	87	3	0	0	0	0								

Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
IWLPPDFFELLAR	4	4	1	2	7	6	8	4	61	2						
LETIVQLER	5	15	33	11	36											
QQLTELYR	19	21	34	26												
YPLTESQALVR	5	8	6	4	17	14	29	17								
DIFQHLR	20	23	57													
IPFPTDK	5	64	31													









#### Relative Contribution of Transition to Signal (%)

Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
DMLSAEALALR	7	6	8	9	11	33	23	4								
LLGLLAEALR	3	17	22	3	56											
SIPTCPFAGSCEVSK	5	2	3	3	16	10	4	48	6	2	1	1				
SLPIEDQISLLK	5	10	4	5	11	36	9	19								
TLGAHTR	5	5	40	50												
AQOTPVLSLK	6	6	2	37	23	26										
EQEELR	31	27	43													
YTIEDGAR	17	13	23	47												
CLDAGMR	12	28	59													




#### Relative Contribution of Transition to Signal (%)

Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
CLEVNANK	5	16	22	56												
ISERDALGEVVAR	10	6	7	12	13	16	20	7	2	6						
LDATEFACKL	7	11	22	20	16	23										
LLLLPALR	0	29	21	20	29											
QTVSLAQPTPK	1	13	4	18	8	36	11	9								
TIGNVPITR	0	27	4	4	54											
AVPTHSQSELR	2	2	13	29	14	7	32									
ILDIPCK	32	10	58													
LLFMSK	5	6	89													
LLSDMYK	6	3	31													
QVALYFR	42	14	44													
SISPTIEEVFFK	15	4	5	17	10	7	10	19	14							
YPTOPCR	45	14	42													




#### Relative Contribution of Transition to Signal (%)

Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
AVEGQHNYLCAGR	17	18	38	8	4	12	1	1	0							
GDVMDPK	9	26	47	18												
GIQDATTGVSEIENPQNK	3	48	10	1	8	5	2	2	13	1	6	2				
GSVSNACQDLSK	6	2	46	6	9	12	8	12	1							
LOTVYCOASFPGANIGNK	16	10	2	4	2	2	39	8	8	7	1	1				
LLFEEMALR	4	16	28	9	14	11	20									
SOELFDEIR	6	12	28	21	34											
TLLLSVPK	2	3	14	24	24	33										
VSASSPLAVASQDSK	1	5	2	10	16	10	13	3	4	28	4	2	0			
MTLNLMLGGR	9	10	5	18	13	9	37									
LLVDFPK	11	10	80													
SSASTAVSAAPTEK	2	23	9	7	24	15	11	4	3	2						
CLOAGMILNLR	5	3	7	5	29	32	19									
COSSGDNLSTLGTINFFGR	31	11	10	5	3	16	5	9	8	1	1					
MTLPCMDQCK	4	8	8	11	7	60	3									
QSSANLFCFAPDLINR	0	11	11	4	5	3	38	13	9	7						




#### Relative Contribution of Transition to Signal (%)


Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
FILFSLDK	8	70	2	1	9	10										
FQDLLLCLVEVR	11	7	6	16	23	17	10	10								
ILGCLQEPK	13	5	6	9	5	62										
MADQTFRISVDWAR	9	11	9	6	27	16	13	7	1	1						
NNLLIEMLQAK	5	6	8	18	32	24	8									
VSYVHGLTCECK	12	4	8	14	11	4	27	17	3							
ALSMQAK	3	6	92													
CLTVGMK	18	15	67													
FLNNHLVK	14	11	11	14	50											
HLGEMPR	9	2	5	84												
QEFVCLK	50	22	27													
SRPDQPAFGLLGR	2	1	4	4	3	4	25	44	2	11						




Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
ALGEGAPPAWR	5	1	13	24	7	25	4	21								
EVILPYSAHQGAPQR	15	2	6	3	8	9	7	6	7	3	34	1				
IATLLLAR	10	28	15	47												
MODLNLAMDALR	9	6	10	24	10	15	6	19								
NYILLGSSLOELR	3	4	4	5	9	40	16	10	8	2						
EEQQQLR	31	33	25	11												
FPHLVPASLGLAAVQAFSK	8	4	7	7	6	8	6	2	8	4	3	1	35			




Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
EPGAAASSAWK	2	4	11	23	33	22	1	4								
LNFNSPCLDYK	8	3	9	3	34	19	14	11								
SLDVLEALFAK	8	5	7	10	19	8	18	24								
INLPESR	4	64	32													



Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
AAGAAIAGQASLPVLQVDR	0	1	29	6	1	29	4	9	6	2	7	5	1			
AAYMADHLK	9	6	34	29	21											
ANLLDSMFGSPGGLR	1	1	18	6	19	19	6	10	14	4	0					
EAQILPCGLCGK	7	1	4	3	61	20	1	3								
ELEMHTSSK	20	9	20	21	16	16										
HSEGFNSFCINQR	11	4	10	12	9	5	3	11	21	14						
HSTEMLHNLNQR	3	8	10	21	27	11	8	4	8							
LESFPELMTAAK	2	6	4	5	3	51	5	25								
LGENGLPSEDPRDQGR	17	0	20	3	1	6	1	48	1	1	0	0				
QSIANGSPSCDMMAPK	16	7	9	4	7	19	15	6	9	5	3					
QSNVQLVPPAR	1	49	8	24	7	7	2									
QVACEICGK	25	15	19	11	30											
SVIEICQEVK	4	5	5	26	26	23	11									
VFGDILDFAVTSR	5	8	8	14	20	23	6	2	13							
VGDESFFPAHR	4	59	14	20	6	4										
VNDASCGPSGCTYQVSR	12	18	12	10	8	5	9	2	12	13						
YPCPEGSSFFR	2	2	8	10	5	56	16									
COTCNASFATR	11	8	16	12	10	15	28									
DVYHLNR	27	37	36													
FCDVLLR	10	20	70													
SHDGSVKPYICSCGK	6	14	4	14	5	2	40	3	11	2	1					
VFTDANR	22	11	66													
GFSRPDHLGHK	5	16	12	7	49	1	10	0	0							
LSHSGEKYSPCVGCLR	2	7	0	7	5	4	3	58	11	2						




Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
ALAPPLAAK	2	1	14	42	42											
ASASLPGSPGDSGLK	0	5	3	0	7	2	3	5	72	1	1	0				
DPCNSLALR	12	16	9	14	19	19	10									
EEIAVWTLTEAR	3	6	3	9	17	39	12	9	1							
THFTSQLELEATQR	13	11	23	15	5	5	10	10	5	2						
YPDMSTR	11	32	57													




#### Relative Contribution of Transition to Signal (%)

Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
AEWIEAK	5	12	19	64												
DAWAFETGAHAGQPK	27	1	5	7	10	4	3	13	14	7	5	3	1			
DDTHYIGASSK	13	13	8	10	24	28	3	0								
EEISLSTVELSGTVVK	3	3	9	10	7	16	8	10	23	4	7	1				
GNVGNLFK	4	3	52	28	14											
GSUSALEDNGVPTGK	4	2	54	3	3	3	6	8	6	3	7	0	0			
QNTLYYK	44	34	11	12												
SSPNMEGGSTYK	5	4	17	12	17	19	14	11								
TQTSTEVFLEACSR	6	16	13	12	14	14	6	5	5	7						
VQQLHSLR	15	24	19	42												
LPPHSILHR	1	13	12	28	46											
SDLAEGFLDDSTALYFAESYK	13	9	15	10	18	15	8	6	3	3	2					
TFLGSSLDWLSNSFTASR	5	8	5	5	5	28	15	11	7	8	3					
DPAFLHYDPSK	62	5	4	7	12	6	3	0								
MHDSNTGIR	1	3	3	24	69											




#### Relative Contribution of Transition to Signal (%)

Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
ITTPYMTK	8	7	40	45												




#### Relative Contribution of Transition to Signal (%)

Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
FENLQLSFK	14	12	13	10	50											
LVEEPIDMSPEIR	0	9	15	9	8	13	3	39	3	1						
MAEELNLEK	5	11	14	20	49											
TSLNQLFSISK	4	17	14	8	22	10	20	6								
WLEEAQVQALYNEK	9	14	9	4	31	11	5	8	6	2	0					
TTISAAK	4	11	24	61												




#### Relative Contribution of Transition to Signal (%)


Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
EDLQLGAIHHR	12	11	8	6	39	18	4	0								
FEGLQLSFK	8	7	9	3	72											
GVLETHFLK	8	7	23	28	34											
LKPLLNK	4	1	95													
TSIEVSVK	6	10	29	55												
WLEEADSTGSPSIDK	4	7	1	21	6	13	9	9	11	11	7	2				




Peptides	Relative Contribution of Transition to Signal (%)																	
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18		
AEALAVDIVSQGK	3	16	7	8	5	14	14	17	12	2	1							
ELEFAER	29	30	23	18														
LGVTQADVGSALANLK	6	9	4	4	5	25	8	15	17	5	3	0						
IAIAIAEK	10	8	82															
TSAIAPEK	18	13	33	35														
VWFENQR	4	17	78															
YPSLHSSSEAIR	5	6	3	9	29	29	6	13										
IPOVGLSLSOSTICR	2	4	7	6	20	7	8	31	3	12								
MNKPELNGGEK	1	4	4	6	6	5	72	3										
SLEAYFAVQPRPSSSEK	0	0	4	1	30	16	13	19	14	1	1							




Peptides	Relative Contribution of Transition to Signal (%)																	
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18		
AEALAVDIVSHQK	4	13	10	5	13	13	19	19	3	2								
ELEFAER	24	32	26	18														
FSSLHSGSEAMR	6	1	2	12	38	34	3	4										
IPOVGLSLSOSTICR	2	4	7	5	21	8	8	28	3	13								
LGVTQADVGSALANLK	5	9	5	6	4	25	8	14	16	5	3	0						
QPFGMHPVLOEPEK	6	6	8	2	50	13	2	6	7									
NSKPELFGSER	1	3	3	5	7	2	80	1										




Peptides	Relative Contribution of Transition to Signal (%)																	
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18		
AIFQFANLDINDOVTLTK	21	15	3	6	4	9	10	18	5	6	3							
CLSVGMSHNAIR	3	5	5	11	6	37	10	24										
DOMLVAYGNIFTR	4	2	3	3	19	18	35	13	2	0								
KPFCDIMEPK	10	8	19	7	31	26												
LHLQSNHPDDILFPK	35	9	7	12	6	1	22	3	2	4								
LVANGIQNK	4	2	8	12	74													
MEGEIVHRLR	5	16	22	4	20	33												
QLVTEHAQLVQIK	9	17	8	6	8	16	17	5	11	4								
TESDAALHPLLOEYR	3	2	3	4	2	59	19	5	2	0								
AEULTCEHDIEDSETADLK	15	11	12	4	22	7	6	8	8	7								
ASNNPPFVHDMETLCMAEK	16	13	17	5	9	3	7	9	14	7								
IFHCDOCTSVETYTELFEAK	18	10	19	11	4	15	3	7	8	2	2							
IVEAYLK	6	18	75															
ASGYHYGHVHACEGK	16	5	10	14	16	3	19	14	4	0								




Peptides	Relative Contribution of Transition to Signal (%)																	
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18		
FMSAYEQR	5	13	9	73														
WQYLLMAAEPIETIAFK	7	20	4	1	1	19	9	13	12	10	3							
MEKPPAPPSLPAGPPGVK	1	4	8	5	1	17	2	2	6	33	3	8	11					
NHLQSYECK	4	3	6	51	37													
QFFLQHFHK	14	24	19	19	24													
EAPAQPAPEK	55	4	24	4	4	9												
MDFQHRPQEK	5	19	6	17	3	50												




Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
ASPFGELQK	7	1	4	27	29	32										
CLSPGSAFSLGPDGGGGGSLR	2	2	1	2	2	2	16	1	7	21	4	2	33	4	1	0
EAVSGLVSGYDWTLPMPVR	7	1	62	12	3	3	4	3	2	3						
LADYPHLHNAELSK	13	5	6	8	15	7	5	39	3	0						





Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
ASYPALASPEAR	28	41	19	11												
VAVVNSLGLNCR	9	2	3	5	5	8	3	50	9	6	0					
TLESLTQLAIK	12	7	6	7	22	8	22	11	5							
VSTIGYLNDHDVTK	4	10	5	10	5	15	15	8	25	2	1					
AMTNLEK	5	7	88													
TCLVDGK	19	19	62													



Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
AGDDEEESCFSSALEYIK	17	16	10	7	9	16	9	6	6	7						
AVLLAEAR	1	36	15	19	6	11	13									
GDFPAAAGNLOTCLAVLGR	1	11	13	11	32	18	14									
AVLLAEAR	43	4	12	28	14											
AVLLAEAR	18	1	39	4	9	10	6	1	6	7	4					
AVLLAEAR	15	27	36	10	12											
AVLLAEAR	4	5	4	5	22	19	9	19	5	7						
AVLLAEAR	5	9	39	23	24											
AVLLAEAR	18	46	22	13												
AVLLAEAR	1	1	21	43	32											
AVLLAEAR	21	45	28	6												
GDFPAAAGNLOTCLAVLGR	18	13	9	3	5	9	9	5	4	15	7	3				
GDFPAAAGNLOTCLAVLGR	9	5	2	7	18	23	9	8	17	1	1					
GDFPAAAGNLOTCLAVLGR	2	2	53	17	12	5	7	2	1							
GDFPAAAGNLOTCLAVLGR	1	26	9	29	15	11	10									
GDFPAAAGNLOTCLAVLGR	0	5	4	5	4	2	6	1	73							
GDFPAAAGNLOTCLAVLGR	3	9	10	23	8	17	19	9	1							
GDFPAAAGNLOTCLAVLGR	3	8	9	26	39	13	2									
GDFPAAAGNLOTCLAVLGR	21	13	13	17	36											
GDFPAAAGNLOTCLAVLGR	0	2	22	11	9	3	19	4	11	9	7	2				
GDFPAAAGNLOTCLAVLGR	6	8	6	15	8	5	12	3	31	5	1					
GDFPAAAGNLOTCLAVLGR	27	41	12	19												
GDFPAAAGNLOTCLAVLGR	11	11	7	26	40	6										
GDFPAAAGNLOTCLAVLGR	15	15	9	7	13	12	28									
GDFPAAAGNLOTCLAVLGR	5	11	23	29	7	26										
GDFPAAAGNLOTCLAVLGR	4	3		16	42	16	19									



Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
WLCNPLQK	10	6	39	11	34											
AIFHACR	30	28	42													
LMAQASPTR	7	8	5	19	61											
THQLLESLR	5	14	10	15	20	35										
ADGQSSFFCHCR	14	15	13	12	13	25	7	0	0							
SSVTFWR	17	56	27													
VFLHEATVR	2	20	33	28	16											
YLQGVNKK	13	38	16	32												





(Page 1)

Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
AGATLLEGLVQELQK	7	11	10	13	3	19	14	14	6	2	1					
ATISEQQAQ	2	4	7	48	30	8										
AVDGYVKPQIK	1	39	15	16	4	7	19									
EAQTLOQYR	17	39	17	23	4											
ENLVFLAQK	11	14	48	20	7											
FSDSEIGGITAWK	14	5	8	3	8	36	17	3	3	3						
HILYNEQR	1	5	16	79												
HLQINQTFEELR	4	3	4	6	4	19	20	38								
IQAGFQAQLQSLSPQER	1	29	23	8	8	13	6	5	5	3						
LAEIQWR	10	37	31	12	11											
LGHYATQLQK	8	4	12	33	45	1										
LVTQDTENELK	2	6	4	13	27	7	40									
QQTILDEDELQWK	12	11	5	4	5	15	24	18	2	3						
QVBLEAWLR	10	14	24	18	5	29										
VPFVAPDK	39	8	19	34												
YYTFVPLAK	9	3	28	59												
AEHVGEDGFLFK	8	1	19	8	1	26	27	7	2							
CPLELVR	24	35	42													
EANNSSPAGSLVADAMSQK	11	6	9	16	8	16	2	6	1	19	4	3				
HVEELLR	10	13	78													
LNVMNPPQVK	1	8	49	12	16	11	3									
LQQTQEIFYIQYESLR	6	6	7	14	17	20	13	12	5							
LSPPALQTSAR	2	5	11	3	16	17	35	11								
QMVLYGQHPFIEVR	3	1	35	12	9	2	19	15	3	2						
QPPVLLK	27	8	65													


(Page 2)

Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
QQLAGNGPPESLDVLSWCEK	15	10	33	12	11	6	1	1	4	4						




Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
ATISEQQAQ	2	4	7	49	30	8										
ATLLEGLVQELQK	6	9	10	14	4	24	20	10	3	0						
AVDGYVKPQIK	1	34	15	18	4	8	19									
EANNSSPAGSLADAMSQK	12	7	8	7	8	4	2	10	2	27	7	2	3			
EAQTLOQYR	16	39	16	23	6											
ENLVFLAQK	10	14	48	20	8											
FSDSEIGGITAWK	13	4	8	2	9	37	17	4	3	3						
HLQINQTFEELR	5	3	4	6	5	20	20	36								
IQAGFQAQLQSLSPQER	1	22	17	7	8	7	1	12	18	7	1					
LAEIQWR	9	37	31	12	11											
LGHYATQLQNTYDR	3	5	8	7	12	7	15	30	13							
LNVMNPPQVK	1	7	41	17	17	13	3									
LQQTQEIFYIQYESLR	5	7	5	15	17	24	13	8	5							
LVTQDTENELK	2	6	4	12	29	8	40									
LNVMNPPQVK	2	1	41	29	11	12	5									
QQTILDEDELQWK	11	8	4	5	6	18	25	17	3	3						
QVBLEAWLR	10	14	23	18	5	30										
VPFVAPDK	38	8	19	36												
YYTFVPLAK	1	1	3	6	2	45	3	33	7							
AEHVGEDGFLFK	6	2	18	5	2	31	28	8	1							
CPMELVR	22	30	48													
HILYNEQR	1	4	15	80												
QPPVLLK	24	11	65													
VLWVQLCEALNMK	6	4	6	3	8	14	3	52	2							


Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
EDSSLNPAK	1	26	18	34	10	5	6									
LQISITQTSVSNVVIAMSGISK	2	7	15	11	24	12	7	2	4	2	11	3				
MQLNSFSQQLNR	4	6	5	4	11	8	10	32	13	7						
VPFVVEEALDVKK	16	11	13	8	9	7	13	14	5	1	2					
WQEMPLQPK	2	1	7	73	10	7										
VDEIEIOL	10	10	23	58												




Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
FAEDLKPOPMK	2	30	1	38	11	7	6	3	2							
GLSGFPLVK	4	1	24	12	10	14	35									
KPPVDQAGPQPPGR	1	0	2	1	3	5	3	1	68	4	2	10				
ENQITR	63	25	12													
LMENPR	22	23	55													
TEVAELR	5	29	66													



Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
AWAELNR	6	26	12	56												
DFGYICETFPK	24	11	3	6	5	26	20	1	4							
DNLFGVWVNFVCSVPR	51	5	7	7	6	3	1	1	16	4	0					
EFTDLAQR	9	38	26	9	8	11										
IGLNLPAGR	2	57	13	24	5											
LSLSSTSK	2	6	30	28	34											
GLPHQLSGLDPR	10	2	10	21	23	23	7	4								
LSPPECLNASLGGVLR	5	4	15	9	6	16	12	15	7	8	1	0				
SNSNAVSAPFNK	1	54	5	4	19	10	3	2	2							
VTVAEYGR	8	15	34	43												
GPVSLSK	6	44	50													




Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
AALPQLSGLDPR	3	1	9	21	15	4	45	1								
AWSEYLR	7	20	7	66												
EFTDLAQR	9	37	27	8	7	12										
IGLNLPAGR	1	57	13	24	5											
LSLSSTSK	2	6	30	29	34											
DFGYICETFPK	24	12	3	6	6	26	19	2	3							
LSPPECLNASLGGVLR	4	4	17	11	6	13	11	17	7	7	2	1				
QEVGSEAGSLLPQPR	1	41	13	5	5	12	8	3	2	7	4					
VTVAEYGR	5	5	46	59												
YEDYDR	5	29	12	53												




Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
AESNDGPHLK	18	7	20	4	20	10	5	16								
ASPTQLNAVEFLWDPAK	24	12	8	4	9	12	7	6	11	7						
DDLVOICPADGR	11	3	0	6	19	26	16	16	2	0						
DYLALPIK	0	19	14	30	37											
LFASFSGADLK	3	2	1	9	17	11	19	38								
LGDFGLNTK	12	17	19	21	20	11										
LPPLOLYLCAATSPAVK	0	24	7	8	8	6	13	13	9	9	3					
LQYTEHQLEGWR	14	9	10	10	14	20	8	10	5							
ASAFVAVHCISTEFTPR	5	8	2	5	14	7	21	27	8	4						
IANLYSISPOHHR	4	3	0	16	30	7	23	17	1	0						
MITYVQCELEQR	4	19	8	9	5	32	16	7	0							







Peptides	Relative Contribution of Transition to Signal (%)																	
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18		
AAPLPAQPSK	2	6	3	68	4	16												
FLTENVSGTPEYDQLK	3	1	22	7	0	31	3	8	19	3	2							
GCLLSQFR	7	27	33	33														
GGFYPVTLR	2	3	47	18	29													
NNLMSLEGALPTPK	27	3	20	7	2	9	8	4	11	8	1							
SDFEYTLGSK	12	8	6	17	31	15	10											
SGESPMAYLNK	11	11	8	5	43	21	1											
VFGWNLSTDFSSQK	8	10	7	7	8	24	8	6	14	3	6							
ETEDYDALJK	12	5	8	11	39	14	6	6										
GVFLNLDITYDGLQTER	1	14	3	4	16	7	13	13	17	13								
TCSPTFEPEPLPSK	38	2	21	5	5	5	5	6	2	10								
TSPEPPCPEDYPLSK	1	14	21	2	2	17	3	8	31	0								
GLALSSNK	6	92	2	0														
ILSSSTGGR	2	7	15	7	69													
SGGAAPAGPSSSNR	8	19	39	7	7	3	2	1	11	3	1							
YGFPEENYK	2	4	6	6	78	3												





Peptides	Relative Contribution of Transition to Signal (%)																	
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18		
AQLGELLQOIAFK	16	8	8	13	18	14	9	8	3	2								
MGMFSQLESQK	12	6	3	23	18	29	8											
CSLEDLK	19	30	51															
YVDALNVLMMANNISK	11	5	9	9	14	16	21	5	7	2	1							
FIDSDFSQK	1	6	9	4	11	68												
MIISTPQR	6	5	32	56														
WGLPNTSAQEQNLEIK	22	19	8	9	2	13	11	6	6	4								



Peptides	Relative Contribution of Transition to Signal (%)																	
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18		
AAEMELQK	10	13	31	46														
ASDVALPR	12	52	15	22														
GELESPKPLVTPGSTLTLLTR	2	2	2	1	1	1	2	32	22	8	2	25						
YNAYPSEQEK	2	1	3	65	12	17												
DWLYLHR	14	44	42															
LLPDMLR	14	14	72															
DPNQFTISR	9	25	36	19	12													



Peptides	Relative Contribution of Transition to Signal (%)																	
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18		
CSQSDGLAPPQHLR	2	3	1	4	61	17	2	7	2	1	0							
ELNLELEK	12	15	31	11	31													
GEPHELPSGSK	27	7	23	20	18	3	0	1	0									
TCPVQLWVSTPPPGTR	1	4	6	44	4	7	9	10	11	4	1							
ALPNTSSSPQPK	1	10	7	13	22	12	15	8	13									
LGFLHSGTAK	0	3	31	36	23	5												
SVTCTYSPALNK	4	1	19	18	17	21	9	10										
QSQHMTEVVR	8	5	26	38	18	6												
TYGQSYGR	8	5	5	33	47													





#### Relative Contribution of Transition to Signal (%)

Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
CATLYCQPIYQR	3	1	44	1	18	15	12	5	1							
EFNEGQAPPSHLR	1	2	1	3	51	24	10	2	5	1	0					
ETYEMLLK	19	36	25	19												
FVETPAHFSWK	5	8	7	3	39	15	23									
IBISMOCR	7	9	10	32	42											
LFRVSLINPOQR	1	25	20	15	9	6	15	3	5							
QLHFSSPSHLR	2	2	2	14	10	17	29	17	6							
ONTHIQMTSK	12	10	7	11	6	34	12	6								
QTSIQSPSSYGNSSPPLNK	1	7	50	5	3	2	9	3	2	2	12	4				
SATWYSTELEK	3	4	11	19	45	17	6									
SPODELLYLR	19	17	24	19	11	4	3	3								
TPSASSTVSGSSETR	0	2	4	18	8	25	9	9	14	4	4	3				
VEGNHAQYVEDPITGR	2	1	67	4	4	6	6	5	5	1	0					
VMTPPGAVIR	1	1	5	3	21	31	31	9								
DEWDFDMAR	8	8	17	12	19	13	11	11	1							
LYCQIAK	5	6	90													
QTSIFPPR	37	12	34	18												
TCPIQIK	3	2	95													
ADEDSIR	23	28	48													
AEHYTEVVK	7	17	26	36	13											
CPNHLSR	19	28	34	20												
DDQVLR	40	55	5													
ICACPR	22	15	63													

#### Relative Contribution of Transition to Signal (%)

Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
GASFEAASGLPOAR	1	23	5	6	14	23	13	10	3	3	0					
LQMDALVAEEAEAK	3	5	3	5	9	33	25	10	4	3	0					
LLENQLLR	4	3	19	25	49											
LTHLSPEEK	2	19	38	29	12											
MSELEGGVVDLEENQK	9	7	12	10	8	19	21	10	3	1						
THGLVVENQLR	1	1	6	8	19	18	6	41								
DPVYQPFLLQWGR	2	3	5	4	2	7	72	3	2							
GNEVIRPAGSAEALR	1	3	23	2	2	1	7	9	2	49	0	0				





#### Relative Contribution of Transition to Signal (%)

Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
APPPGWFLQPR	1	1	14	2	2	7	26	48								
DAAAILLDEQNK	2	7	17	22	31	14	6	2								
DLOELSIQVEEER	6	10	9	14	11	30	12	8	1							
FLITGDCFSNCR	4	5	17	15	8	14	4	18	12	3						
SFGDMLNHR	23	10	19	26	22											
YFCDYGR	6	21	29	52												
TTVFGYVQWPPVQELPPLSR	4	3	40	5	1	2	0	2	37	1	2					
VWYDMFR	12	12	76													
HLNGLDQLK	20	3	2	16	59											


#### Relative Contribution of Transition to Signal (%)

Peptides	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
AGEPESGGAWEALER	3	9	12	8	11	22	10	9	6	2	4	3				
DTQGVTLQLPSPR	2	57	7	6	4	4	14	5	2	0						
EVPOVSYLDSPLQFQVEER	9	8	5	1	40	8	2	2	17	8						
LNHLRHR	18	35	27	8	12											
LSPOCEGK	14	6	15	40	12	12										
SFTQNYDLR	12	14	14	30	19	19										
SPPGENPSQGLPSPSSR	6	2	12	3	33	9	1	6	1	14	2	11				
SYVCPNGK	7	4	45	23	20											
VPELDLQK	7	16	13	13	28	23										
EIQSWVR	14	52	34													
IHLQPR	13	16	71													
EPGRPWVWLK	40	9	3	39	2	8										
LNLDLQGWLRPER	89	7	5	2	2	7	3	3	1							
SSTEAGGEVQTSK	10	6	5	2	9	37	23	6	2							



Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
DILQMELOASPCGK	5	2	28	20	14	7	8	9	5	2	0					
LYLGGAPR	0	5	37	57												
VDGDQASFMMNCR	10	15	17	12	27	14	3	1	2							
SYSQSSALLQHR	9	17	11	13	14	22	5	8								
DFWMSNLHQLK	8	13	17	4	6	8	26	15	2							
QVSVLIQHQR	10	20	19	19	6	27										
SFQSSGFLR	2	10	10	35	6	37										
SHPCDICTPLR	7	4	5	10	14	7	6	47								
SVFIQHR	10	35	25	29												
VHTGERPYECEGK	1	8	4	5	3	0	14	65	0	0						


Peptides	Relative Contribution of Transition to Signal (%)															
	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18
AFSSSLLR	4	5	6	15	5	15										
AFSSSNIIEHR	19	14	6	7	14	25	4	10								
AFSSSLEIQR	15	18	12	7	11	13	18	2	5							
EKPYVNLCKG	8	3	5	16	13	7	49									
FOETAFEMR	8	20	30	21	17	4										
GLEGMAYIK	22	12	19	20	14	13										
LESQGLFPGEDLGDFFLQHR	8	5	1	49	2	5	5	3	1	2	21					
SALIEHYK	10	24	36	29												
AFCHSALDHQR	10	16	9	9	7	14	26	8	1							
GSSHILR	56	25	19													
SFNSGSLQHR	7	17	5	16	19	26	7	4								




## **SUPPLEMENTARY DATA LEGENDS**

**Supplementary Data 2. Comparison of our empirical rankings with peptide rank predictions from the ESPPredictor algorithm**


**ATOH7**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.82)**




**BHLHB2**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.83)**




**CCDC16**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.47)**





**CLOCK**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.49)**






### E2F5

#### ESPPredictor vs. Empirical SRM intensities




#### ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.38)




### ERG

#### ESPPredictor vs. Empirical SRM intensities




#### ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.34)




### ETS2


#### ESPPredictor vs. Empirical SRM intensities




#### ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.62)




**EWSR1**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.82)**




**EZH2**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.099)**




**FOSB**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.57)**




**FOSL2**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.77)**




**FOXN1**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank**  
(Spearman=-0.053)




**FOXR2**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank**  
(Spearman=0.48)




**GATA2**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank**  
(Spearman=0.79)



**GATA3**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank**  
(Spearman=0.64)







**GF11**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.53)**




**GMEB1**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.32)**




**GMEB2**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.78)**




**GTF2H4**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.85)**




**HOXA10**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank**  
(Spearman=0.8)




**HOXA5**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank**  
(Spearman=0.69)




**HSF4**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank**  
(Spearman=0.27)



**HSFY2**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank**  
(Spearman=0.29)







**LEF1**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.45)**




**LHX4**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.71)**




**LIN28**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.6)**




**MAD**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.71)**




**MAX**  
ESPPredictor vs. Empirical SRM intensities




ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=-0.45)




**MEF2A**  
ESPPredictor vs. Empirical SRM intensities




ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.36)




**MEF2C**  
ESPPredictor vs. Empirical SRM intensities




ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.57)





**MYB**  
ESPPredictor vs. Empirical SRM intensities




ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.66)






### MYC

#### ESPPredictor vs. Empirical SRM intensities




#### ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.39)




### MYF6

#### ESPPredictor vs. Empirical SRM intensities




#### ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.49)




### NFE2


#### ESPPredictor vs. Empirical SRM intensities




#### ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.6)




**NFIA**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.35)**




**NFKB1**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.28)**




**NR113**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.59)**







**NR2E1**  
ESPPredictor vs. Empirical SRM intensities







**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.65)**






**OLIG1**  
ESPPredictor vs. Empirical SRM intensities







**PITX3**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.091)**




**PLEK2**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.62)**




**POU3F4**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=-0.26)**




**POU4F1**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.29)**




**POU4F3**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.79)**




**PPARA**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.48)**




**SF3A2**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.2)**




**SOX10**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.24)**




**SOX5**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.72)**




**SREBF2**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.4)**




**STAT5A**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.55)**




**STAT5B**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.66)**




**TAF11**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.38)**




**TEF**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.024)**




**TFAP2A**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.7)**




**TFAP2B**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.74)**




**TFCP2L1**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.6)**




**TFCP2L4**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.59)**




**T FDP2**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.28)**




**TGIF2**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.13)**




**TP53**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.56)**




**TP73L**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.23)**




**XBP1**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.03)**




**ZMAT5**  
ESPPredictor vs. Empirical SRM intensities




**ESPPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.76)**




**ZNF496**  
ESSPredictor vs. Empirical SRM intensities




**ESSPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.61)**




**ZNF70**  
ESSPredictor vs. Empirical SRM intensities




**ESSPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.48)**



**ZNF74**  
ESSPredictor vs. Empirical SRM intensities



**ESSPredictor Rank vs. Empirical SRM Intensity Rank (Spearman=0.42)**



# Skyline Absolute Quantification

---

## Introduction

This tutorial covers how to determine the absolute abundance of a target protein using Selected Reaction Monitoring (SRM) mass spectrometry. Specifically, we will demonstrate how to use an external calibration curve with an internal standard heavy labeled peptide.

Peptide absolute abundance measurements can be obtained using either a single-point or a multiple-point calibration. Single-point calibration absolute abundance measurements are generated by spiking into a target sample a heavy labeled 'standard' version of the target peptide that is of known abundance. The absolute abundance of the 'sample' target peptide is obtained by calculating the relative abundance of the light 'sample' target peptide to the heavy 'standard' target peptide<sup>22</sup>. One drawback is that this approach assumes that a light-to-heavy ratio of 2 implies that the light peptide is actually twice as abundant as the heavy peptide – this is referred to as having a peptide response with a slope of 1. Furthermore, this approach of using a single point calibration makes the assumption that both the light and the heavy peptide are both within the linear range of the mass spectrometry detector. However, these assumptions are not always correct<sup>23,24,25,26</sup>.

Multiple-point calibration experiments correct for situations where the peptide response does not have a slope of 1. This calibration is done by measuring the signal intensity of a 'standard' peptide at multiple calibration points of known abundance and generating a calibration curve. This calibration curve can then be used to calculate the concentration of the target peptide in a sample, given the signal intensity of that peptide in that sample<sup>24</sup>. One drawback is that this method requires multiple injections into the mass spectrometer to build a calibration curve.


To improve the precision of absolute abundance measurements using an external calibration curve, stable isotope labeled internal standards are often used<sup>27</sup>. Imprecise measurements of the ion intensity of a peptide often arise from sample preparation, autosampler or chromatographic irregularities. By adding an identical quantity of a standard heavy labeled peptide to each of the calibrants and the sample, one is able to measure the ratio of calibrant-to-standard or sample-to-standard. This approach is favored as this ratio is unaffected by some sample preparation, autosampler or chromatographic irregularities. Consequently, by performing peptide absolute quantification using an external calibration curve and an internal standard heavy labeled peptide one is able to obtain the most accurate and precise measurements while minimizing the amount of valuable sample that has to be used.



## Experimental Overview

This tutorial will work with data published in Stergachis et al. 2011 where the absolute abundance of GST-tagged proteins were measured using a 'proteotypic' peptide present within the GST-tag (**Tutorial Figure 1A**). For any absolute quantification experiment, it is critical to first identify one or more 'proteotypic' peptides that will be used to quantify the protein of interest. The peptide IEAIPQIDK was identified as 'proteotypic' based on its strong signal intensity relative to other tryptic peptides in the GST-tag (unpublished). Also, this peptide uniquely identifies this schistosomal GST-tag as opposed to other human glutathione-binding proteins.

For this experiment, FOXN1 protein containing an in frame GST-tag was generated using *in vitro* transcription/translation and full-length proteins were purified using glutathione resin (**Tutorial Figure 1B**). Heavy labeled IEAIPQIDK peptide was then spiked into the elution buffer and the sample was digested and analyzed using selected reaction monitoring (SRM) on a Thermo TSQ Vantage triple-quadrupole mass spectrometer. An external calibration curve was generated using different quantities of a light IEAIPQIDK peptide that was purified to >97% purity and the concentration determined by amino acid analysis. Heavy labeled IEAIPQIDK peptide was also spiked into these calibrants at the same concentration as in the FOXN1-GST sample (**Tutorial Figure 1C**). It is important to note that it does not matter what the concentration of the heavy peptide is in each of the samples, so long as it is the same. However, it is best if the amount of heavy peptide in the samples is similar to the amount of light peptide originating from FOXN1-GST. Also, it is best if the concentration of the light peptide originating from FOXN1-GST falls somewhere in the middle of the concentration range tested using the different calibrants.



### Tutorial Figure 1. Experimental Overview

(A) Schistosomal GST-tag protein sequence. The tryptic peptide used for quantification purposes is indicated in red.

(B) Schematic of the synthesis, enrichment, digestion and analysis of tagged proteins.

(C) Samples monitored and the abundance of light and heavy IEAIPQIDK peptide in each.

## Getting Started

First, please check

(<https://skyline.gs.washington.edu/labkey/wiki/home/software/Skyline/page.view?name=tutorials>) to ensure that this tutorial is up-to-date. Periodic revisions of this tutorial will occur as additional features are added to Skyline.

To start this tutorial, download the following ZIP file:

<https://skyline.gs.washington.edu/tutorials/AbsoluteQuant.zip>

Extract the files in it to a folder on your computer, like:

C:\Users\absterga\Documents

This will create a new folder:

C:\Users\absterga\Documents\AbsoluteQuant


Now start Skyline, and you will be presented with a new empty document.

## Generating a Transition List

Before you insert a peptide sequence into Skyline, it is important to make sure that all of the peptide and transition settings are correctly configured for this experiment. The settings described below are designed for  $^{13}\text{C}_6^{15}\text{N}_2$  L-Lysine labeled internal standard peptides. If you are using a different isotope, please choose the appropriate isotope modification in the Peptide settings configuration.







### Configuring Transition settings:

- On **Settings** menu, click **Transition Settings**.
- Click the **Prediction** tab.
- Choose **Monoisotopic** for the **Precursor mass** and the **Product ion mass**.
- From the **Collision energy** drop-list choose the instrument that you will be using for your measurements. For this experiment, a **Thermo TSQ Vantage** was used for all measurements.
- Click the **Filter** tab.
- For these experiments we monitored doubly charged precursors (**Precursor charges**), and singly charged (**Ion charges**)  $y_3$  to  $y_{n-1}$  product ions (**Ion types** and **Product Ions From and To**).
- The correct configuration of these tabs can be seen below.




## Configuring Peptide settings:

- On the **Settings** menu, click **Peptide Settings**.
- Click the **Modifications** tab.
- Click the **Edit list** button for **Isotope modifications**.
- Click the **Add** button.
- Choose **Label:13C(6)15N(2) (C-term K)** from the **Name** dropdown list.
- Click the **OK** button.
- Check the new **Label:13C(6)15N(2) (C-term K)** modification in the **Isotope modifications** list.
- Since the experiment uses a heavy labeled internal standard peptide, ensure that the **Internal standard type** drop-list is set to **heavy**.




## Inserting a peptide sequence:

- On the **Edit** menu, choose **Insert** and click **Peptides**.
- Paste *IEAIPQIDK* into the **Peptide Sequence** box and *GST-tag* into the **Protein Name** box.
- Click the **Insert** button.




After performing the above steps, the main screen of Skyline should appear as below. You can save this file as test\_file or whatever you like in the folder you have created for this tutorial.



## Exporting a transition list:

- On the **File** menu, choose **Export** and click **Transition List**.
- The **Export Transition List** form can be configured as desired. Below is what was used for this experiment
- This exported transition list was used to generate an SRM method for a Thermo TSQ Vantage triple-quadrupole mass spectrometer.



## Analyzing SRM Data from Calibrants

In this next section you will work with the nine samples indicated in **Tutorial Figure 1C**. You will import the .RAW files into Skyline to view the data. Data will be imported into the saved Skyline document that was generated in the previous section. The files that you will import are contained in the folder you created for this tutorial and are called:

- Standard\_1.RAW
- Standard\_2.RAW
- Standard\_3.RAW
- Standard\_4.RAW
- Standard\_5.RAW
- Standard\_6.RAW
- Standard\_7.RAW
- Standard\_8.RAW
- FOXN1-GST.RAW

These RAW files were collected in a random order and were interspersed amongst a larger set of runs contained within **Supplemental Data 2** for the original paper ([http://proteome.gs.washington.edu/software/skyline/ivt\\_srm/Supplementary\\_data\\_2.zip](http://proteome.gs.washington.edu/software/skyline/ivt_srm/Supplementary_data_2.zip)).


Before you look at the FOXN1-GST sample, you should first become familiar with the standards.

### Importing RAW files into Skyline:

- On the **File** menu, choose **Import** and click **Results**.
- Click the **Add single-injection replicates in files** option in the **Import Results** form.

- Click the OK button.
- In the **Import Results Files** form, find and select all eight *Standard* RAW files listed above.
- Click **Open** to import the files.
- When presented with the option to remove the 'Standard\_' prefix in creating replicate names, click **Do not remove**.


It may take a few moments for Skyline to import all of the RAW files.



To ensure that the chromatographic peaks for each of the standards looks good, it is best to view all of the traces next to each other in a tiled view.

This can be done by clicking ctrl-T or on the **View** menu, by choosing **Arrange Graphs** and clicking **Tiled**.

If you select the IEAIPQIDK peptide on the left side of the screen, you will see the heavy (Blue) and light (Red) traces loaded into the same window for each standard.



What to inspect when looking at the chromatographic traces for the standards:

- Make sure that the correct peak is selected for both the heavy and light trace of each standard.
- Make sure the peak shapes look Gaussian and do not show an excessively jagged appearance. If this is the case, it may be best to rerun your samples.
- Make sure that the retention time is similar for the different standards. Widely varying retention times often indicate poor chromatography.

## Analyzing SRM Data from FOXN1-GST Sample

Next you will want to import the FOXN1-GST.RAW file into the current Skyline document using the same instructions as detailed above. To ensure that this sample looks good, we will inspect the chromatographic trace, the fragmentation pattern and the retention time of both the heavy and light peak.


Because this is already a refined method, on the **Settings** menu, click **Integrate All**.

To focus on just the FOXN1-GST data, on the **View** menu, choose **Arrange** and click **Tabbed** (Ctrl-Shift-T), and click on the FOXN1-GST tab.

The **Retention Time** comparison graph can be displayed by pressing F8 or on the **View** menu, by choosing **Retention Times** and then clicking **Replicate Comparison**.

The **Peak Areas** comparison graph can be displayed by pressing F7 or on **View** menu, by choosing **Peak Areas** and then clicking **Replicate Comparison**.

To view the relative contribution of each transition to the total signal intensity, you can right-click on the **Peak Areas** graph, choose **Normalized To** and click **Total**.








You can then select either the light or heavy precursor and inspect to ensure that:

- The correct peak is selected for both the heavy and light trace.
- The peak shape looks Gaussian and does not show an excessively jagged appearance.
- The retention time is similar for the standards and the FOXN1-GST sample.
- The relative contribution of each transition to the total signal is similar for each sample. If this does not appear to be so, then an incorrect peak is likely selected for one of the samples.

Another way to view the data is to select the IEAIPQIDK peptide in the Peptide View to the left, as opposed to the individual light and heavy precursor ions.

To view the light-to-heavy ratio for each standard and the FOXN1-GST sample, you can right-click on the **Peak Areas** graph, choose **Normalized To** and click **Heavy**.

The values displayed in this **Peak Areas** graph will be the ones we use to build our calibration curve. It can be easily observed from this graph that the light-to-heavy ratio for the FOXN1-GST sample falls somewhere in the middle of the ratios from our calibration points. This is ideal, as this portion of the calibration curve is best for quantification purposes.




## Generating a Calibration Curve

For this tutorial, you will make a calibration curve using Microsoft Excel. However, this can be done using other graphical or statistical programs such as R.

## Exporting data from Skyline:

- On the **File** menu, choose **Export** and click **Report**.
- Click **Edit List** and then **Add** to specify the columns that will appear in the report.
- For this experiment you will want to have identifying features for each sample, as well as the **RatioToStandard** (See below for the parameters included).
- Once the report is configured, you can provide a **Report Name**.



- Click **OK**.
- Click **OK** in the **Edit Reports** form.
- Click **Export** in the **Export Report** form.
- Enter 'Calibration.csv' in the **File name** field of the save form that appears.
- Click **Save**.

When opened in Excel, the exported report should look like this:

	A	B	C	D	E
1	PeptideSequence	ProteinName	ReplicateName	RatioToStandard	
2	IEAIPQIDK	GST-tag	Standard_1	21.4513	
3	IEAIPQIDK	GST-tag	Standard_2	6.2568	
4	IEAIPQIDK	GST-tag	Standard_3	2.0417	
5	IEAIPQIDK	GST-tag	Standard_4	0.8244	
6	IEAIPQIDK	GST-tag	Standard_5	0.2809	
7	IEAIPQIDK	GST-tag	Standard_6	0.1156	
8	IEAIPQIDK	GST-tag	Standard_7	0.0819	
9	IEAIPQIDK	GST-tag	Standard_8	0.0248	
10	IEAIPQIDK	GST-tag	FOXN1-GST	0.7079	
11					


To generate a calibration curve, you first need to specify for each standard the concentration of the light IEAIPQIDK peptide. These values can be found in **Tutorial Figure 1C** and are also displayed below.

Once these known concentrations are entered, you can display the calibration curve by selecting the values, as indicated below, and clicking the **Insert** tab and then **Scatter Plot**.

A trendline for the calibration curve can be generated by right-clicking on the data points within the graph and selecting **Add Trendline**. From the trendline options, you will want to select **Linear Regression**. In more recent versions of Excel, you will also want to make sure the check boxes are checked to display the equation and the R-squared value on the chart.

Now inspect the trendline to ensure that:

- None of the standards drastically depart from it.
- The data points still appear to follow the trendline even at the lower concentration points.
- The  $R^2$  value is high, indicating a good fit.



## Calculating the Concentration of the FOXN1-GST Sample

To calculate the concentration of the light IEAIPQIDK peptide within the FOXN1-GST sample you will use the calibration curve from the previous section. This will allow you to calibrate the light-to-heavy ratio of IEAIPQIDK within the FOXN1-GST sample to known concentrations. To do this, you must first identify the slope and intercept of the calibration curve.


To do this, you can select two adjacent cells in Excel and type into the equation dialog:

**=LINEST(E2:E9,D2:D9)**

*E2:E9 are the y-values (Concentration)*

*D2:D9 are the x-values (light-to-heavy ratio)*

Then press **ctrl-shift-Enter** and the Slope and Intercept will be displayed in the two selected cells



Using this linear equation the concentration of any unknown sample (y-value) can be obtained by inserting the light-to-heavy ratio of that sample (x-value) into a standard  $y = m \cdot x + b$  equation ( $concentration = slope \cdot ratio + intercept$ ).


We can do this for the FOXN1-GST sample in excel by typing into a cell:

**=B32\*D10 + C32**

*B32 is the slope of the linear regression*

*D10 is the light-to-heavy ratio of the FOXN1-GST sample*

*C32 is the Intercept of the linear regression*



This yields the value 1.86 as the concentration of FOXN1-GST within our sample. This concentration is in units fmole/ $\mu$ l or nM, as this is the concentration of our calibrants used for the linear regression.

Since the purified FOXN1-GST reaction was resuspended in 100  $\mu$ l total volume, we can state that there are 189 femtomoles, or  $1.13 \cdot 10^{11}$  molecules of FOXN1-GST within our sample.

## Conclusion

This tutorial presented the advantages of different absolute abundance experimental setups and demonstrated how to determine absolute abundances using an external calibration curve with an internal standard heavy labeled peptide. This method provides accurate and precise absolute measurements while minimizing the amount of valuable sample that has to be used during the experiment.

## Reference List

22. Gerber, S.A., Rush, J., Stemman, O., Kirschner, M.W. & Gygi, S.P. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. *Proceedings of the National Academy of Sciences of the United States of America* **100**, 6940-6945 (2003).
23. MacCoss, M.J., Wu, C.C., Matthews, D.E. & Yates, J.R. Measurement of the isotope enrichment of stable isotope-labeled proteins using high-resolution mass spectra of peptides. *Analytical Chemistry* **77**, 7646-53 (2005).
24. Lavagnini, I. & Magno, F. A statistical overview on univariate calibration, inverse regression, and detection limits: Application to gas chromatography/mass spectrometry technique. *Mass spectrometry reviews* **26**, 1-18
25. Watson, J.T. Mass Spectrometry. *Methods in Enzymology* **193**, 86-106 (1990).
26. Patterson, B.W. & Wolfe, R.R. Concentration dependence of methyl palmitate isotope ratios by electron impact ionization gas chromatography/mass spectrometry. *Biological mass spectrometry* **22**, 481-6 (1993).
27. MacCoss, M.J., Toth, M.J. & Matthews, D.E. Evaluation and optimization of ion-current ratio measurements by selected-ion-monitoring mass spectrometry. *Analytical chemistry* **73**, 2976-84 (2001).